Physician profile
Roberto Olivarez
NPI 1144395302
$19,617.70
in general payments reported to CMS, 2019-2025
25 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,149 · 2020: $1,202 · 2021: $1,982 · 2022: $2,378 · 2023: $4,355 · 2024: $2,380 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,276 · Travel and Lodging: $1,614 · Entertainment: $16.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,276.15 |
| Travel and Lodging | $1,614.40 |
| Entertainment | $16.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $8,062.93 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Biotissue Holdings INC. | $2,209.25 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $1,495.98 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Coopervision INC. | $1,238.39 | 2019-2024 | Myday Contact Lens, Misight Contact Lens, Biofinity Contact Lens |
| Oyster Point Pharma, INC. | $930.24 | 2022-2024 | Tyrvaya |
| Lumenis Be INC | $848.78 | 2025 | M22 |
| Allergan, INC. | $775.99 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $719.92 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $516.81 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $504.04 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $467.74 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $423.87 | 2019-2021 | |
| Dompe US, INC. | $276.48 | 2023-2025 | Oxervate |
| Shire North American Group INC | $205.91 | 2019 | |
| Sight Sciences, INC. | $174.35 | 2022-2023 | Tearcare System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $148.46 | 2025 | Vevye |
| Abbvie INC. | $146.50 | 2022-2023 | |
| Lkc Technologies, INC. | $137.05 | 2024 | |
| Rxsight INC | $103.41 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $94.60 | 2019 | |
| Eyevance Pharmaceuticals LLC | $43.47 | 2020 | |
| Abb Con-Cise Optical Group LLC | $41.03 | 2023 | Contact Lens, Spectacle Lenses |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $16.74 | 2024 | |
| Optos, INC. | $16.36 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Olivarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.